Publication | Closed Access

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses

MedicineAntiviral Drug DevelopmentAntiviral TherapyMolecular BiologyVirologyResistance Mutation (Virology)Antiviral DrugHivWide RangePharmacologyAntiviral CompoundBiomolecular EngineeringDrug DiscoveryDrug Resistance